Medical Oncologist
Medicines
How long will you be on pertuzumab?
In early HER2-positive breast cancer, pertuzumab and trastuzumab are usually planned to complete about a year of HER2-targeted treatment, though surgery results can change the medicines used. In advanced cancer, the antibodies usually continue for as long as they keep the cancer controlled. This page explains, in general terms, how treatment length is decided and what to expect.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- How long is pertuzumab usually given?
- Four common treatment courses
- How the treatment time is divided
- Treatment length terms, in plain language
- Honest realities about treatment length
- Who continues pertuzumab after surgery
- Fitting a year of treatment into your life
- What people assume about how long pertuzumab lasts
- Common questions about how long you take pertuzumab
The short answer
How long is pertuzumab usually given?
How long you take pertuzumab depends mainly on whether your breast cancer is early or advanced. In early HER2-positive breast cancer, pertuzumab is given with trastuzumab every three weeks, and the aim is usually to complete about one year of HER2-targeted treatment in total. Many people start before surgery, with pertuzumab, trastuzumab and chemotherapy for a few months to shrink the cancer. What happens after surgery depends on what the surgeon removes. If no invasive cancer is left, the antibodies usually continue to complete the year, sometimes with pertuzumab and sometimes with trastuzumab alone, depending on how high the original risk was. If some cancer remains, doctors commonly switch to a different medicine, trastuzumab emtansine, instead of continuing pertuzumab. When surgery comes first, pertuzumab may be added after surgery for cancers with a higher chance of returning, such as those that had spread to lymph nodes. In advanced, or metastatic, HER2-positive breast cancer there is no fixed end date. Chemotherapy is usually given for several months and then stopped, while pertuzumab and trastuzumab continue for as long as they keep the cancer under control and side effects remain manageable. For some people that means many months or years. Hormone therapy may also be added if the cancer is hormone receptor positive. Your oncologist will explain your own plan.
Early cancer: about a year
The antibodies are usually planned to complete roughly one year of HER2-targeted treatment.
Surgery results can change the plan
Remaining cancer after treatment before surgery often leads to a switch in medicine.
Advanced cancer: open-ended
Treatment continues while it is working and side effects are acceptable.
This page gives general information only. Your treatment length is decided by your oncologist.Different paths
Four common treatment courses
Your course usually follows one of these broad patterns.
Before surgery
Pertuzumab, trastuzumab and chemotherapy for several cycles, then surgery. The antibodies are counted towards the planned year.
After surgery, no cancer left
The HER2 antibodies usually continue every three weeks until about a year of treatment is complete.
Radiotherapy and hormone therapy can run alongside.After surgery, cancer remains
Trastuzumab emtansine often replaces pertuzumab and trastuzumab for the rest of the course.
Advanced cancer
Antibodies continue after chemotherapy stops, with regular review.
Treatment is reviewed if
- Scans show the cancer is growing
- Side effects become hard to manage
- Heart pumping strength falls and does not recover
Phase by phase
How the treatment time is divided
Phase
What usually happens
Combination phase
Antibodies with chemotherapy for several cycles
Surgery, in early cancer
A short break around the operation, then treatment resumes
Antibody-only phase
Pertuzumab and trastuzumab every three weeks, often with radiotherapy
End of planned year
Antibodies stop, and follow-up and hormone therapy continue if needed
Advanced cancer maintenance
Antibodies continue with scans every few months
Words you will hear
Treatment length terms, in plain language
- Neoadjuvant treatment
- Treatment given before surgery to shrink the cancer.
- Adjuvant treatment
- Treatment given after surgery to lower the chance of the cancer returning.
- Residual disease
- Invasive cancer still found in the breast or nodes at surgery.
- Maintenance treatment
- Ongoing treatment after chemotherapy stops, to keep advanced cancer controlled.
- Disease progression
- When scans show the cancer is growing or spreading despite treatment.
- Cycle
- One treatment visit and the rest period after it, here three weeks long.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
Honest realities about treatment length
A year of treatment, or open-ended treatment, is a long commitment. It is fair to ask why it takes this long and what happens if plans change.
Why a year?
Large trials of trastuzumab set one year as the standard. Shorter courses have been studied, and some doctors use them in selected situations, but a year remains the usual plan.
Plans do change
Heart changes, side effects or surgery results can shorten, pause or alter your course.
Longer is not always better
Studies of two years of trastuzumab did not show extra benefit over one year in early cancer.
What this page cannot tell you
It cannot set your own treatment length. Your oncologist bases this on your cancer, your surgery results and how you tolerate treatment.
After surgery
Who continues pertuzumab after surgery
Not everyone who has HER2-targeted treatment after surgery needs pertuzumab as well as trastuzumab. The extra benefit is small overall and is concentrated in people at higher risk.
Higher-risk cancers
Pertuzumab after surgery is mostly considered for cancers that had spread to lymph nodes, and sometimes for larger or hormone receptor negative cancers.
Lower-risk cancers
For smaller cancers without lymph node spread, trastuzumab alone is often enough to complete the year, which also means fewer loose motions.
Practical factors
Side effects, heart health and access to treatment are all part of the discussion, and it is reasonable to ask how much pertuzumab adds in your case.
Living with a long course
Fitting a year of treatment into your life
Once chemotherapy ends, many people return to much of their usual routine while the antibodies continue.
Work and family
Antibody-only visits every three weeks are often short, and many people work, study or care for family during this phase.
Travel
Short trips can often be planned between cycles. Discuss longer travel with your team so doses are not delayed too much.
Staying motivated
A calendar marking each completed cycle can make the year feel more manageable.
Commonly believed
What people assume about how long pertuzumab lasts
Treatment ends when chemotherapy ends.
The HER2 antibodies usually continue well after chemotherapy stops.
If the scan is clear, I can stop early.
A clear scan does not remove unseen cancer cells, which is why the planned year matters.
Everyone takes pertuzumab for a full year.
Some switch medicines after surgery or complete the year with trastuzumab alone.
In advanced cancer, treatment stops after a set number of cycles.
It usually continues for as long as it is working.
Questions we are asked
Common questions about how long you take pertuzumab
How many cycles of pertuzumab will I have?
In early breast cancer, treatment every three weeks for about a year adds up to around eighteen cycles of HER2-targeted treatment, but not all of them are necessarily pertuzumab. Some people switch to trastuzumab alone or trastuzumab emtansine after surgery. Your team will count your cycles and explain how many remain.
Does treatment before surgery count towards the year?
Yes. Cycles of pertuzumab and trastuzumab given before surgery are usually counted towards the total. After surgery, the remaining cycles are given to complete roughly a year of HER2-targeted treatment, unless the surgery results lead your team to change medicines.
Why would I switch to trastuzumab emtansine?
If invasive cancer remains after treatment before surgery, a large study showed that trastuzumab emtansine lowered the chance of the cancer returning compared with continuing trastuzumab. It usually replaces the antibodies for the rest of the year. Your team will discuss whether this applies to you.
Can radiotherapy be given at the same time?
Yes. Pertuzumab and trastuzumab are commonly continued during radiotherapy after surgery, so the year of treatment is not interrupted. Your radiotherapy and oncology teams coordinate the timing, and heart scans continue as planned throughout.
How long does it continue in advanced cancer?
There is no fixed end point. Pertuzumab and trastuzumab usually continue for as long as scans show the cancer is controlled and side effects are acceptable. Some people stay on them for many months or several years, with regular reviews of benefits and side effects.
Can I take a break from treatment?
In advanced cancer, planned breaks are sometimes discussed, but they are not routine and carry uncertain risks. In early cancer, doctors aim to keep the schedule, with pauses only for side effects, heart changes or surgery. Talk openly with your team if treatment is becoming hard to continue.
Will I also take hormone therapy?
If your cancer is also hormone receptor positive, hormone therapy is usually started after chemotherapy and can run alongside the antibodies. It typically continues for years after pertuzumab has finished, and its length is planned separately by your oncologist.
What happens after my last dose?
You move into follow-up, with regular clinic visits, yearly mammograms and any ongoing hormone therapy. A final heart scan may be done. Contraception is still needed for several months after the last dose, and your team will explain which symptoms to report in future.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Cancer Research UK — Pertuzumab (Perjeta)
- National Cancer Institute — Pertuzumab
- European Medicines Agency — Perjeta: product information
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.